Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY, Sept. 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its Saragene™ dengue and chikungunya RT-PCR tests as in vitro diagnostics ("IVD").

Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests

SALT LAKE CITY, Sept. 13, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion hosted by Scott Gottlieb, M.D.

Co-Diagnostics, Inc. CEO to Participate in Panel Discussion with Scott Gottlieb, M.D., at H.C. Wainwright 2021 Annual Global Investor Conference

Co-Diagnostics Inc. reports that its Logix Smart COVID-19 Test Kit was used by Italian researchers to confirm the presence of SARS-CoV-2, including mutated strains of the virus.

Co-Diagnostics says its Logix Smart COVID-19 Test Kit used to confirm presence of coronavirus including mutated strains in Italy

SALT LAKE CITY, Sept. 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Italian researchers to confirm the presence of SARS-CoV-2, including mutated strains of the virus, in a community surveillance method of testing single-use waste, with the peer-reviewed results published in the journal Science of the Total Environment.

Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy

SALT LAKE CITY, Aug. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting and hosting a booth this week at the 13th Annual Next Generation Dx Summit on Aug 24-26 in Washington, D.C. The Next Generation Dx Summit, offering complete coverage of timely and important issues for the diagnostics industry, is comprised of the Enabling Point-of-Care Diagnostics testing (POCT) stream, and the Companion Diagnostics and Liquid Biopsy stream.

Co-Diagnostics, Inc. To Present At 13th Next Generation Dx Summit In Washington, D.C.

Co-Diagnostics shares rallied after the company posted strong quarterly results. Total addressable market expanding.

Why Co-Diagnostics Is A Solid Covid-19 Play

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

CoDiagnostics, Inc. (CODX) Just Reclaimed the 20-Day Moving Average

The company notched beats on both trailing and anticipated revenue and earnings.

Why Co-Diagnostics Zoomed Almost 10% Higher Today

Co-Diagnostics Inc's (NASDAQ: CODX) Q2 revenue increased 14% Y/Y to $27.4 million, primarily due to Logix Smart COVID-19 Test sales, beating the consensus of $20.77 million. Gross profit increased 37.6% to $24.9 million, with margin expanding to 90.8% from 75.1% in Q2 FY20 due to reduced production costs and improved product mix compared to the prior-year period.

Co-Diagnostics Stock Moves Higher As Q2 Earnings Top Estimates

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q2 2021 Results - Earnings Call Transcript

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 43.48% and 30.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Surpasses Q2 Earnings and Revenue Estimates

Co-Diagnostics (NASDAQ:CODX) Inc posted second-quarter results that saw pre-tax income of $11.9 million and year-over-year revenue gains driven by sales of the company's Logix Smart COVID-19 Test. For the period ended June 30, 2021, the Salt Lake City, Utah-based molecular diagnostics company reported revenue of $27.4 million, up 13.8% from the second quarter in 2020.

Co-Diagnostics sees 2Q revenue rise by 13.8% driven by sales of the Logix Smart COVID-19 Test

SALT LAKE CITY, Aug. 12, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Financial Results: Revenue of $27.4 million, primarily due to sales of the Logix Smart™ COVID-19 Test, representing an increase of 13.8% as compared to the prior year period.

Co-Diagnostics Reports Strong Second Quarter 2021 Financial Results

SALT LAKE CITY, Aug. 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2021 results on Thursday, August 12, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces Second Quarter 2021 Earnings Release Date And Webcast

The company was awarded a patent from a relatively affluent Asian country.

Why Co-Diagnostics Blasted 21% Higher on Thursday

Co-Diagnostics Inc (NASDAQ:CODX) shares are trading higher by 26.3% at $10.99 Thursday afternoon. The stock spiked earlier following reports suggesting the Biden Administration will announce it is directing $1.6 billion for COVID testing in high-risk settings.

Why Co-Diagnostics Shares Are Skyrocketing Today

Co-Diagnostics Inc has strengthened its intellectual property portfolio after being awarded a patent in the Republic of Korea for the company's CoPrimer technology. Developed in 2013, Co-Diagnostics' solely owned CoPrimer technology received its first patent from the United States Patent Office in 2018, and underpins the company's molecular diagnostic test products deployed in laboratories and hospitals in over 50 countries and across the US.

Co-Diagnostics strengthens intellectual property portfolio with South Korean patent award for its CoPrimer technology

SALT LAKE CITY, July 22, 2021  /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual property protection after being awarded a patent from the Republic of Korea's Intellectual Property Office for the Company's CoPrimer™ technology. Developed in 2013, Co-Diagnostics' solely-owned CoPrimer technology received its first patent from the United States Patent Office in 2018, and underpins the Company's molecular diagnostic test products that have been deployed in laboratories and hospitals in over 50 countries and across the United States.

Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer™ Patent

The stock price of Co-Diagnostics Inc (NASDAQ: CODX) increased by 9.67% yesterday. This is why it happened.

CODX Stock Increased 9.67%: Why It Happened

CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in CoDiagnostics, Inc. (CODX): Can Its 9.7% Jump Turn into More Strength?

BioNTech SE

Moderna

Novavax

Pfizer

Vaxart

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Why Coronavirus Stocks Are Zooming Higher Today

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing CoDiagnostics, Inc. (CODX) Right Now?

Co-Diagnostics, Inc. (NASDAQ:CODX) has announced that its Logix Smart SARS-CoV-2 DS (Direct Saliva) test has obtained regulatory authorization to be sold as an in vitro diagnostic (IVD) for the diagnosis of coronavirus (COVID-19) in markets that accept CE markings. The company noted that the test is available now for purchase from its Utah-based ISO-13485:2016 certified facility.

Co-Diagnostics, Inc. says its Logix Smart cornavirus test has obtained regulatory authorization to be sold in markets that accept CE markings

SALT LAKE CITY, June 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2 DS (Direct Saliva) has obtained regulatory authorization to be sold as an in vitro diagnostic ("IVD") for the diagnosis of COVID-19 in markets that accept CE markings, and is now available for purchase from the Company's Utah-based ISO-13485:2016 certified facility. Co-Diagnostics' Logix Smart DS test kit is designed to detect the presence of the RdRp and E genes of SARS-CoV-2 directly from minimally processed human saliva samples while eliminating RNA extraction of the samples, a costly and time-consuming process required by most PCR tests.

Co-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test

Co-Diagnostics, Inc. (NASDAQ:CODX) said it will be presenting virtually this week at the 28th International Biodetection Technologies Conference, as well as hosting a virtual booth at the 65th Annual Caribbean Public Health Agency (CARPHA) Health Research Conference. The International Biodetection Technologies Conference is being held on June 18, 2021.

News for Co-Diagnostics Stock (CODX)